PubMed Central, : RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2014 October; 5(4): e0041. ISSN: 2076-9172Published online 2014 October 29. doi: 10.5041/RMMJ.10175.

Table 3.

Adverse Effects of Long-Term Use of Low-Molecular Weight Heparin and Vitamin K Agonist.^*

Study	n	Treatment	Thrombocytopenia (%)	HIT (%)	Bruising (%)	Allergy (%)	Fracture (%)
CANTHANOX	71	VKA	24	0	–	–	0
CANTHANOX	67	LMWH	32	0	–	–	0
CLOT	336	VKA	–	–	–	–	–
CLOT	336	LMWH	–	–	–	–	–
LITE	100	VKA	4	–	–	–	5
LITE	100	LMWH	6	–	–	–	3
ONCENOX	34	VKA	14	0	–	–	–
ONCENOX	68	LMWH	3	0	–	–	–
MALT	154	Placebo	–	0	–	1	–
MALT	148	LMWH	–	0	–	0	–
FAMOUS	184	Placebo	–	–	–	–	–
FAMOUS	190	LMWH	–	–	–	–	–
SIDERAS	70	Placebo	2	–	19	–	–
SIDERAS	68	LMWH	5	–	50	–	–

^*n=500 patients with cancer. HIT, heparin-induced thrombocytopenia; LMWH, low-molecular weight heparin; VKA, vitamin K agonist. Reprinted with permission from Debourdeau et al.⁵⁶

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2014 October; 5(4): e0041. ISSN: 2076-9172

Published online 2014 October 29. doi: 10.5041/RMMJ.10175